证券代码：000516 证券简称：国际医学 公告编号：2026-005 西安国际医学投资股份有限公司 第十三届董事会第十次会议决议 公 告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 西安国际医学投资股份有限公司董事会于 2026 年 3 月 18 日以书 面方式发出召开公司第十三届董事会第十次会议的通知，并于 2026 年 3 月 23 日以通讯表决方式召开。会议应参加表决董事 9 人，实际 参加表决的董事 9 人。会议的召开符合有关法律、法规、规章和《公 司章程》的规定。 经会议认真审议和投票表决，通过了下述决议： 一、通过《关于为子公司提供担保的议案》（9 票同意、0 票反 对、0 票弃权）； 公司本次继续为全资子公司西安高新医院有限公司提供的最高 额度为人民币 80,000 万元的连带责任担保是为了保证子公司业务发 展的资金需求。被担保对象为公司全资子公司，公司为其提供担保的 财务风险可控，不存在与《上市公司监管指引第 8 号——上市公司资 金往来、对外担保的监管要求》《深圳证券交易所上市公司自律监管 指引第 1 号——主板上市公司规范运作》等有关 ...

证券代码：000516 证券简称：国际医学 公告编号：2026-006 西安国际医学投资股份有限公司 关于为子公司提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 本次担保为以前年度担保的延续，担保发生后公司及子公司对外担 保总额将超过公司最近一期经审计净资产100%（均为公司对全资子公 司或控股子公司的担保），其中对资产负债率超过70%的全资及控股二 级子公司提供的担保超过公司最近一期经审计净资产50%，请投资者充 分关注担保风险。 一、担保情况概述 由于公司2021年对全资子公司西安高新医院有限公司提供的最高 额度为人民币80,000万元的连带责任担保将于近日到期，为了保障子公 司运营的正常资金需求，经西安国际医学投资股份有限公司（以下简称 "国际医学"或"公司"）第十三届董事会第十次会议审议通过（9票 同意、0票反对、0票弃权），公司拟继续为全资子公司西安高新医院有 限公司提供最高额度为人民币80,000万元的连带责任担保，担保额度有 效期为五年。并授权公司管理层办理担保相关手续。上述担保事项不涉 及关联交易，尚需经公司股东会审 ...

证券代码：000516 证券简称：国际医学 公告编号：2026-007 西安国际医学投资股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市 规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法 律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （3）本公司聘请的律师。 8、会议地点：西安市高新区西太路 777 号西安国际医学中心医院南院区保障楼 6 层 会议室。 二、会议审议事项 （1）现场会议时间：2026 年 04 月 08 日 14:55 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 04 月 08 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投 票的具体时间为 2026 年 ...

Market Overview - A-shares and Hong Kong stocks showed a collective strength today, with A-shares opening lower but rising throughout the morning session [1][2] - The Shanghai Composite Index rose by 0.25%, the Shenzhen Component increased by 0.8%, the ChiNext Index gained 0.85%, and the Sci-Tech Innovation Index climbed 1.29% [4] Sector Performance - The pharmaceutical and biotechnology sector experienced a significant surge, with the sector rising over 2% and multiple stocks hitting the daily limit [5] - The agricultural sector also performed well, with gains exceeding 3%, highlighted by stocks like Xiangjia Co. and Dunhuang Seed Industry reaching their daily limits [5] - Other sectors such as environmental protection, basic chemicals, construction decoration, social services, and military industry also saw notable increases [7] Notable Stocks - Key stocks in the pharmaceutical sector included: - Yahui Pharmaceutical-U (688176) with a price of 16.78, up 20.03% [6] - Huakang Clean (301235) at 56.43, up 11.94% [6] - International Medicine (000516) at 5.01, up 10.11% [6] - The virtual power plant concept stocks performed strongly, with the index surging over 3% and several stocks hitting their daily limits [9] New Listings - The newly listed stock, Gude Electric Materials, saw its price increase by over 150% during trading. The company specializes in thermal runaway protection components for electric vehicle batteries and high-performance insulation products for electrical applications [12] Hong Kong Market - The Hong Kong market also showed positive momentum, with the Hang Seng Index rising nearly 2% and the Hang Seng Technology Index increasing by over 3% [14] - Major stocks in the Hang Seng Technology Index, such as JD.com, Trip.com, and NetEase, saw price increases exceeding 5% [16]

Group 1 - The company, International Medical (000516.SZ), stated that it is not currently involved in any work related to space internet hospitals [1]

Core Viewpoint - The company reported that its medical institutions have been operating well since obtaining IVF qualifications in 2022, but they have not yet reached the five-year mark required to apply for PGT qualifications [2] Group 1 - The company's IVF operations have been running smoothly since the approval of qualifications in 2022 [2] - According to the regulations on assisted reproductive technology management, a minimum of five years of operation is required before applying for PGT qualifications [2] - Currently, the company's IVF operations have not yet completed five years [2]

Core Viewpoint - The company has experienced stable development in its overall medical business, with increasing discipline strength and steady revenue growth, but the revenue scale has not yet covered operational costs and period expenses [1] Group 1: Business Performance - The company reported a year-on-year decline in revenue due to market fluctuations and adjustments in DRG payment policy reform [1] - The company is implementing measures to adjust its business structure and enhance cost efficiency, leading to a reduction in the loss margin in the fourth quarter [1] Group 2: Future Outlook - The company has provided a performance forecast for 2025, indicating potential challenges due to industry dynamics [1]

Core Viewpoint - Investors express concerns about International Medical's financial stability, highlighting issues such as a stock price hovering around 5 yuan, a major shareholder's pledge ratio nearing 80%, and significant short-term debt pressures [1] Group 1: Financial Concerns - The stock price of International Medical is fluctuating around 5 yuan, indicating potential investor anxiety [1] - The major shareholder's pledge ratio is approaching 80%, which raises concerns about financial leverage and risk [1] - The company faces significant short-term debt pressures, which could impact its operational flexibility [1] Group 2: Company Response - International Medical acknowledges investor concerns and expresses gratitude for their attention [1] - The company plans to implement a differentiated strategy to build competitive advantages and improve operational performance [1]

Group 1 - The company, International Medicine (000516), responded to investor inquiries on February 13, indicating that any significant information regarding the company should be based on official disclosures [1]

Core Viewpoint - International Medical (000516) has shown a decline in revenue and profit for the first three quarters of 2025, indicating potential challenges in its business operations and financial health [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 2.995 billion yuan, a year-on-year decrease of 16.94% [2]. - The net profit attributable to shareholders was -294 million yuan, down 38.45% year-on-year [2]. - The net profit after deducting non-recurring items was -312 million yuan, a decline of 41.94% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 961 million yuan, a decrease of 18.95% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -129 million yuan, a significant drop of 234.24% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -123 million yuan, down 52.03% year-on-year [2]. - The company's debt ratio stood at 68.8%, with investment income of 20.7586 million yuan and financial expenses of 111 million yuan [2]. - The gross profit margin was 6.59% [2]. Market Activity - As of February 10, 2026, the stock closed at 4.96 yuan, with an increase of 0.4% [1]. - The turnover rate was 1.55%, with a trading volume of 341,700 hands and a transaction amount of 169 million yuan [1]. - On February 10, the net inflow of main funds was 15.2399 million yuan, accounting for 8.99% of the total transaction amount [1]. - Retail investors experienced a net outflow of 280,100 yuan, representing 0.17% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, two institutions have given ratings for the stock, both recommending an increase in holdings [3]. - The average target price set by institutions over the past 90 days is 5.5 yuan [3].